Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study

INTRODUCTION: Little evidence appears to exist for the use of anakinra, a recombinant interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone or combined with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammatory state. PATIENTS A...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Intern Emerg Med
Главные авторы: Aomar-Millán, Ismael Francisco, Salvatierra, Juan, Torres-Parejo, Úrsula, Faro-Miguez, Naya, Callejas-Rubio, José Luis, Ceballos-Torres, Ángel, Cruces-Moreno, María Teresa, Gómez-Jiménez, Francisco Javier, Hernández-Quero, José, Anguita-Santos, Francisco
Формат: Artigo
Язык:Inglês
Опубликовано: Springer International Publishing 2021
Предметы:
Im - Original
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782569/
https://ncbi.nlm.nih.gov/pubmed/33400157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11739-020-02600-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы